Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3379-3396

  Pisick, Evan ^a   Skarin, Arthur T ^a   Salgia, Ravi ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NONE   (United States)

Author keywords

Carcinoid; Diagnosis; Ewing's sarcoma; Merkel carcinoma; Neuroblastoma; Non Hodgkins lymphoma; Review; Rhabdomyosarcoma; SCLC; Small blue cell tumors; Therapy

Indexed keywords

ALPHA2A INTERFERON; ANGIOSTATIN; BATIMASTAT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NUCLEOSIDE ANALOG; PACLITAXEL; PEPTIDE HORMONE ANTAGONIST; PEROXIDASE; PREDNISONE; RITUXIMAB; SURAMIN; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL TRIAL; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG EFFICACY; EWING SARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE THERAPY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MERKEL CELL TUMOR; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; TREATMENT OUTCOME; TUMOR CELL;

CARCINOID TUMOR; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; LYMPHOMA, SMALL-CELL; NEUROBLASTOMA; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SARCOMA, SMALL CELL;

EID: 0042029310     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (250)

1. Bonfill X, Moreno C, Prada G, Riveroe and Rue M: Lung cancer mortality among males of Catalonia and Spain compared with other European countries between 1975-1977 and 1987-1989. Int J Cancer 65(6): 751-754, 1996.
2. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT and Sugarbaker DJ: Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13(5): 1265-1279, 1995.
3. Remick SC, Hafez GR and Carbone PP: Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) 66(6): 457-471, 1987.
4. Doria MI Jr, Montag AG and Franklin WA: Immunophenotype of small cell lung carcinoma. Expression of NKH-1 and transferrin receptor and absence of most myeloid antigens. Cancer 62(9): 1939-1945, 1988.
5. Otterson G, Lin A and Kay F: Genetic etiology of lung cancer. Oncology (Huntingt) 6(9): 97-112, 1992.
6. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H and Nakamura Y: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7(3): 445-449, 1992.
7. Hu QJ, Dyson N and Harlow E: The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 9(4): 1147-1155, 1990.
8. Sidransky D and Hollstein M: Clinical implications of the p53 gene. Annu Rev Med 47: 285-301, 1996.
9. Yunis JJ and Ramsay N: Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132(2): 161-163, 1978.
10. Taguchi T, Zhou JY, Feder M, Litwin S, Klein-Szanto AJ and Testa JR: Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes. Cancer Genet Cytogenet 89(2): 120-125, 1996.
11. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R et at: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7(2): 339-346, 1992.
12. Sato S, Nakamura Y and Tsuchiya E: Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 54(21): 5652-5655, 1994.
13. Ohata H, Emi M, Fujiwara Y, Higashino K, Nakagawa K, Futagami R, Tsuchiya E and Nakamura Y: Deletion mapping of the short arm of chromosome 8 in non-small cell lung carcinoma. Genes Chromosomes Cancer 7(2): 85-88, 1993.
14. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizoguchi H and Yokota J: Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res 54(21): 5643-5648, 1994.
15. Bepler G and Garcia-Blanco MA: Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci USA 91(12): 5513-5517, 1994.
16. Iizuka M, Sugiyama Y, Shiraishi M, Jones C and Sekiya T: Allelic losses in human chromosome 11 in lung cancers. Genes Chromosomes Cancer 13(1): 40-46, 1995.
17. Otsuka T, Kohno T, Mori M, Noguchi M, Hirohashi S and Yokota J: Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chromosomes Cancer 16(2): 113-119, 1996.
18. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, Phelps RM, Gazdar AF, Ihde DC and Johnson BE: Myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51(6): 1708-1712, 1991.
19. Noguchi M, Hirohashi S, Hara F, Kojima A, Shimosato Y, Shinka T and Tsuchiya R: Heterogenous amplification of myc family oncogenes in small cell lung carcinoma. Cancer 66(10): 2053-2058, 1990.
20. Funa K, Gazdar AF, Mattson K, Niiranen A, Koivuniemi A, Oberg K, Wilander E, Doyle A and Linnoila RI: Interferon-mediated in vivo induction of beta 2-microglobulin on small-cell lung cancers and mid-gut carcinoids. Clin Immunol Immunopathol 41(1): 159-164, 1986.
21. Salgia R and Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 16(3): 1207-1217, 1998.
22. Sekido Y, Fong KM and Minna JD: Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378(1): F21-59, 1998.
23. Pignon JP and Arriagada R: Role of thoracic radiotherapy in limited-stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data. J Clin Oncol 10(11): 1819-1820, 1992.
24. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O 0, Joss RA, Kies MS, Lebeau B et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327(23): 1618-1624, 1992.
25. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83(12): 855-861, 1991.
26. Roth JA: New approaches to treating early lung cancer. Cancer Res 52 (9 Suppl): 2652s-2657s, 1992.
27. Ihde DC: Chemotherapy of lung cancer. N Engl J Med, 327(20): 1434-1441, 1992.
28. Aisner J: Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 14(2): 658-665, 1996.
29. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277(5698): 665-667, 1979.
30. Parness J and Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91(2 Pt 1): 479-487, 1981.
31. Ettinger DS: The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update. Semin Oncol 22(1 Suppl 2): 23-27, 1995.
32. Jett JR, Kirschling RJ, Jung SH and Marks RS: A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol 22(3 Suppl 6): 75-77, 1995.
33. Hainsworth JD, Morrissey LH, Scullin DC Jr, Houston GA, Prasthofer EF, Gray JR, Burris HA 3rd and Greco FA: Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 94(9): 2426-2433, 2002.
34. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H and Kaye SB: Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A(8): 1058-1060, 1994.
35. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85(4): 271-291, 1993.
36. Devore R 3rd, Johnson D, Crawford J, Dimery I, Eckardt J and Eckhardt SG: Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. Oncology (Huntingt) 12(8 Suppl 6): 79-83, 1998.
37. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K and Kishimoto S: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10(11): 1775-1780, 1992.
38. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H and Taguchi T: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83(16): 1164-1168, 1991.
39. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2): 85-91, 2002.
40. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P and Wong D: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5(3): 283-285, 1994.
41. Ardizzoni A, Grossi F, Meazza R and Errini S: New perspectives for the pharmacological and biological therapy of small cell lung cancer. Crit Rev Oncol Hematol 31(2): 135-145, 1999.
42. Brown PD: Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35: 293-301, 1995.
43. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219): 58-61, 1989.
44. Pesenti E, Sola F, Mongelli N, Grandi M and Spreafico F: Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer 66(2): 367-372, 1992.
45. de Cupis A, Ciomei M, Pirani P, Ferrera A, Ardizzoni A and Favoni RE: Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines. Br J Pharmacol 120(3): 537-543, 1997.
46. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2): 315-328, 1994.
47. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H and Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348(6301): 555-557, 1990.
48. Viallet J and Sausville EA: Involvement of signal transduction pathways in lung cancer biology. J Cell Biochem Suppl 24: 228-236, 1996.
49. Moody TW, Carney DN, Cuttitta F, Quattrocchi K and Minna JD: High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci 37(2): 105-113, 1985.
50. Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL and Johnson BE: Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112(1): 256-261, 1997.
51. Langdon S, Sethi T, Ritchie A, Muir M, Smyth J and Rozengurt E: Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 52(16): 4554-4557, 1992.
52. Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K and Miller YE: Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 56(4): 831-839, 1996.
53. Cohen AJ, Gilman LB, Moore M, Franklin WA and Miller YE: Inactivation of neutral endopeptidase in lung cancer. Chest 109(3 Suppl): 12S-13S, 1996.
54. Bunn PA Jr and Carney DN: Overview of chemotherapy for small cell lung cancer. Semin Oncol 24(2 Suppl 7): S69-74, 1997.
55. vanderSpek JC, Sutherland JA, Zeng H, Battey JF, Jensen RT and Murphy JR: Inhibition of protein synthesis in small cell lung cancer cells induced by the diphtheria toxin-related fusion protein DAB389 GRP. Cancer Res 57(2): 290-294, 1997.
56. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5): 561-566, 1996.
57. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y and Takagi H: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6(12): 2291-2296, 1991.
58. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y and Takahashi T: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51(9): 2416-2419, 1991.
59. Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, Tsukamoto T, Hida T, Shimokata K, Zsebo KM et al: Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 53(7): 1709-1714, 1993.
60. RygaardK, Nakamura T and Spang-Thomsen M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67(1): 37-46, 1993.
61. Plummer H 3rd, Catlett J, Leftwich J, Armstrong B, Carlson P, Huff T and Krystal G: c-Myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res 53(18): 4337-4342, 1993.
62. Krystal GW, Hines SJ and Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56(2): 370-376, 1996.
63. Krystal GW, Honsawek S, Litz J and Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6(8): 3319-3326, 2000.
64. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE and Salgia R: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62(21): 6304-6311, 2002.
65. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T and Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2(9): 985-991, 1996.
66. Roth JA: Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53. Hum Gene Ther 7(7): 861-874, 1996.
67. Blackwood EM, Luscher B, Kretzner L and Eisenman RN: The Myc:Max protein complex and cell growth regulation. Cold Spring Harb Symp Quant Biol 56: 109-117, 1991.
68. Kumagai T, Tanio Y, Osaki T, Hosoe S, Tachibana I, Ueno K, Kijima T, Horai T and Kishimoto T: Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res 56(2): 354-358, 1996.
69. Stahel RA: Biology of lung cancer. Lung Cancer 10 (Suppl 1): S59-65, 1994.
70. Epstein MA, Achong BG and Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1: 702-703, 1964.
71. Takatsuki K, Uchiyama T, Sagawa K and Hattori T: Lymphoma and immunoglobulin abnormalities, with special reference to M proteinemia. Nippon Rinsho 35(10): 3757-3767, 1977.
72. Beral V: The epidemiology of cancer in AIDS patients. Aids 5 (Suppl 2): S99-103, 1991.
73. Cesarman E, Chang Y, Moore PS, Said JW and Knowles DM: Kaposi's sarcoma- associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332(18): 1186-1191, 1995.
74. Louie S, Daoust PR and Schwartz RS: Immunodeficiency and the pathogenesis of non-Hodgkin's lymphoma. Semin Oncol 7(3): 267-284, 1980.
75. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR and Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 307(20): 1231-1236, 1982.
76. Tsujimoto Y, Finger LR, Yunis JJ, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226(4678): 1097-1099, 1984.
77. Tsujimoto Y, Gorham J, Cossman J, Jaffe E and Croce CM: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229(4720): 1390-1393, 1985.
78. Tsujimoto Y, Cossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228(4706): 1440-1443, 1985.
79. Cleary ML and Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82(21): 7439-7443, 1985.
80. Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J and Mason DY: Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140(5): 1089-1095, 1992.
81. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL and Arnold A: PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88(21): 9638-9642, 1991.
82. Banks PM: The distinction of Hodgkin's disease from T cell lymphoma. Semin Diagn Pathol 9(4): 279-283, 1992.
83. Harris NL: Mantle cell lymphoma. J Clin Oncol 12(4): 876-877, 1994.
84. Lukas J, Jadayel D, Bartkova J, Nacheva E, Dyer MJ, Strauss M and Bartek J: BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene 9(8): 2159-2167, 1994.
85. Ye BH, Rao PH, Chaganti RS and Dalla-Favera R: Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 53(12): 2732-2735, 1993.
86. Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM, Chaganti RS and Dalla-Favera R: Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 83(7): 1757-1759, 1994.
87. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS and Hanna N: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25(2): 705-708, 1997.
88. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF and Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63(6): 1424-1433, 1984.
89. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, wail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A and Solal-Celigny P: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97(1): 101-106, 2001.
90. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA and Fisher RI: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19(2): 389-397, 2001.
91. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, Dowden S and Levy R: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6(7): 2644-2652, 2000.
92. van der Kolk LE, de Haas M, Grillo-Lopez AJ, Baars JW and van Oers MH: Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 16(4): 693-699, 2002.
93. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I 1, Davis T and Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6): 2188-2195, 1997.
94. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8): 2825-2833, 1998.
95. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B and Varns C: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17(1): 268-276, 1999.
96. Sivaraman S, Venugopal P, Ranganathan R, Deshpande CG, Huang X, Jajeh A, Gregory SA, O'Brien T and Preisler HD: Effect of interferon- alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther 6(2): 81-87, 2000.
97. Herberman RR, Ortaldo JR and Bonnard GD: Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 277(5693): 221-223, 1979.
98. Ortaldo JR, Pestka S, Slease RB, Rubinstein M and Herberman RB: Augmentation of human K-cell activity with interferon. Scand J Immunol 12(5): 365-369, 1980.
99. Wurflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M and Gramatzki M: Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 58(14): 3051-3058, 1998.
100. Stockmeyer B, Elsasser D, Dechant M, Repp R, Gramatzki M, Glennie MJ, van de Winkel JG and Valerius T: Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor- directed bispecific antibodies. J Immunol Methods 248(1-2): 103-111, 2001.
101. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH and Grillo-Lopez AJ: Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5(10 Suppl): 3281s-3286s, 1999.
102. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E and Grillo-Lopez AJ: Phase I/II trial of IDEC-Y2B8 radioimmuno-therapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17(12): 3793-3803, 1999.
103. Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A and Goldenberg DM: Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5(10 Suppl): 3292s-3303s, 1999.
104. DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S and DeNardo SJ: Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res 5(10 Suppl): 3219s-3223s, 1999.
105. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, uan A, Goldstein DS, Carr CE, Mirick GR and DeNardo SJ: A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 40(12): 2014-2020, 1999.
106. Wahl RL: Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J Nucl Med 39(8 Suppl): 1S, 1998.
107. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD and Wahl RL: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14(7): 1974-1981, 1996.
108. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G and Wahl RL: Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4): 1259-1266, 2000.
109. Leonard JP and Link BK: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 29(l Suppl 2): 81-86, 2002.
110. Senderowicz AM: Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19(56): 6600-6606, 2000.
111. Connors JM, Kouroukis C, Belch A et al: Flavopiridol for mantle cell lymphoma: Moderate activity and frequent disease stabilization. Blood 98: 807a, 2001 (abstract).
112. Ewing J: Diffuse endothelioma of bone. Proc New York Pathol Soc 21: 17, 2921.
113. Granowetter L and West DC: The Ewing's sarcoma family of tumors: Ewing's sarcoma and peripheral primitive neuroectodermal tumor of bone and soft tissue. Cancer Treat Res 92: 253-308, 1997.
114. Grier HE: The Ewing family of tumors, Ewing's sarcoma and primitive neuroectodermal tumors, Pediatr Clin North Am 44(4): 991-1004, 1997.
115. Fraumeni JF Jr and Glass AG: Rarity of Ewing's sarcoma among U.S. Negro children. Lancet, 1(7642): 366-367, 1970.
116. Li FP, Tu JT, Liu FS and Shiang EL: Rarity of Ewing's sarcoma in China. Lancet 1(8180): 1255, 1980.
117. Askin FB, Rosai J, Sibley RK, Dehner LP and McAlister WH: Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 43(6): 2438-2451, 1979.
118. Green DM, Marinello MJ, Fisher J, Mindell ER, Zak TA, Allen JE, Khan AR and Brecher ML: Ewing's sarcoma of the scapula with metastases to the lung and eye. Am J Pediatr Hematol Oncol 8(2): 134-143, 1986.
119. Dehner LP: Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol 17(1): 1-13, 1993.
120. Nascimento AG, Unii KK, Pritchard DJ, Cooper KL and Dahlin DC: A clinicopathologic study of 20 cases of large-cell (atypical) Ewing's sarcoma of bone. Am J Surg Pathol 4(1): 29-36, 1980.
121. Triche TJ: Diagnosis of small round cell tumors of childhood. Bull Cancer 75(3): 297-310, 1988.
122. Perlman EJ, Dickman PS, Askin FB, Grier HE, Miser JS and Link MP: Ewing's sarcomaroutine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Hum Pathol 25(3): 304-307, 1994.
123. Ramani P, Rampling D and Link M: Immunocytochemical study of 12E7 in small round-cell tumours of childhood: an assessment of its sensitivity and specificity. Histopathology 23(6): 557-561, 1993.
124. Weidner N and Tjoe J: Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 18(5): 486-494, 1994.
125. Fellinger EJ, Garin-Chesa P, Triche TJ, Huvos AG and Rettig WJ: Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 139(2): 317-325, 1991.
126. Turc-Carel C, Philip I, Berger MP, Philip T and Lenoir GM: Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet Cytogenet 12(1): 1-19, 1984.
127. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Kao-Shan S, Tsai S and Israel MA: Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet 21(3): 185-208, 1986.
128. Douglass EC, Valentine M, Green AA, Hayes FA and Thompson EI: t(11;22) and other chromosomal rearrangements in Ewing's sarcoma. J Natl Cancer Inst 77(6): 1211-1215, 1986.
129. Aurias A, Rimbaut C, Buffe D, Zucker JM and Mazabraud A: Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet Cytogenet 12(1): 21-25, 1984.
130. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G et al: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359(6391): 162-165, 1992.
131. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP et al: Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32(2): 229-238, 1988.
132. Downing JR, Head DR, Parham DM, Douglass EC, Hulshof MG, Link MP, Motroni TA, Grier HE, Curcio-Brint AM and Shapiro DN: Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol 143(5): 1294-1300, 1993.
133. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ and Denny CT: A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6(2): 146-151, 1994.
134. Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman F, Fletchers CD, Urias A and Thomas G: EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 4(4): 341-345, 1993.
135. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT and Shapiro DN: A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10(6): 1229-1234, 1995.
136. Saeter G, Alvegard TA, Elomaa I, Wiebe T, Bjork O, Strander H and Solheim OP: Chemotherapy for osteosarcoma and Ewing's sarcoma. Acta Orthop Scand Suppl 273: 120-125, 1997.
137. Gerald WL, Miller HK and Battifora H: Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol 15(6): 499-513, 1991.
138. Raney RB, Ater JL, Herman-Liu A, Leeds NE, Cleary KR, Womer RB and Rorke LM: Primary intraspinal soft-tissue sarcoma in childhood: report of two cases with a review of the literature. Med Pediatr Oncol 23(4): 359-364, 1994.
139. Pappo AS, Shapiro DN and Crist WM: Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 44(4): 953-972, 1997.
140. Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Tsokos MG, Shimada H, Harms D, Schmidt D et al: Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 76(6): 1073-1085, 1995.
141. Tsokos M: The diagnosis and classification of childhood rhabdomyosarcoma. Semin Diagn Pathol 11(1): 26-38, 1994.
142. Cavazzana AO, Schmidt D, Ninfo V, Harms D, Tollot M, Carli M, Treuner J, Betto R and Salviati G: Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol 16(3): 229-235, 1992.
143. Scrable H, Witte D, Shimada H, Seemayer T, Sheng WW, Soukup S, Koufos A, Houghton P, Lampkin B and Cavenee W: Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1(1): 23-35, 1989.
144. Koufos A, Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC and Cavenee WK: Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 316(6026): 330-334, 1985.
145. El-Badry OM, Minniti C, ohn EC, Houghton PJ, Daughaday WH and Helman LJ: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1(7): 325-331, 1990.
146. Dias P, Kumar P, Marsden HB, Gattamaneni HR and Kumar S: N- and c-myc oncogenes in childhood rhabdomyosarcoma. J Natl Cancer Inst 82(2): 151, 1990.
147. Barr FG: Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19(6): 483-491, 1997.
148. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13(3): 610-630, 1995.
149. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J et al: The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61(2): 209-220, 1988.
150. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J et al: The Intergroup Rhabdomyosarcoma Study-II. Cancer 71(5): 1904-1922, 1993.
151. Castleberry RP: Neuroblastoma. Eur J Cancer 33(9): 1430-1438, 1997.
152. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD and White PS: Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19(2): 93-101, 1997.
153. Matthay KK: Neuroblastoma: biology and therapy. Oncology (Huntingt) 11(12): 1857-1875, 1997.
154. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE and Brodeur GM: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 86(10): 3753-3757, 1989.
155. Brodeur GM, Sekhon G and Goldstein MN: Chromosomal aberrations in human neuroblastomas. Cancer 40(5): 2256-2263, 1977.
156. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL and Tsiatis AA: Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41(11 Pt 1): 4678-4686, 1981.
157. Brodeur GM and Fong CT: Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41(2): 153-174, 1989.
158. Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, Rinaldt V, Vinikoor N and Weisband J: Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res 44(11): 5444-5449, 1984.
159. Lahti JM, Valentine M, Xiang J, Jones B, Amann J, Grenet J, Richmond G, Look AT and Kidd VJ: Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat Genet 7(3): 370-375, 1994.
160. Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT and Brodeur GM: Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55(20): 4664-4669, 1995
161. Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ and Brodeur GM: Physical mapping and genomic structure of the human TNFR2 gene. Genomics 35(1): 94-100, 1996.
162. Enomoto H, Ozaki T, Takahashi E, Nomura N, Tabata S, Takahashi H, Ohnuma N, Tanabe M, Iwai J, Yoshida H et al: Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene 9(10): 2785-2791, 1994.
163. Shapiro DN, Sublett JE, Li B, Valentine MB, Orris SW and Noll M: The gene for PAX7, a member of the paired-box-containing genes, is localized on human chromosome arm 1p36. Genomics 17(3): 767-76 1993
164. Aso T, Lane WS, Conaway JW and Conaway R: Congin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 269(5229): 1439-14431995
165. Kibel A, Iliopoulos O, DeCaprio JA and Kaelin WG Jr: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269(5229): 1444-1446, 1995.
166. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N and Helin K: The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13(12): 7813-7825, 1993.
167. White PS, Maris JM, Beltinger C, Sulman E, Marshall MN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hilliard C et al: A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA 92(12): 5520-5524, 1995.
168. Suzuki T, Yokota J, Mugishima H, Okabe I, Ookuni M, Sugimura T and Terada M: Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 49(5): 1095-1098, 1989
169. Takayama H, Suzuki T, Mugishima H, Fujisawa T, Ookuni M, Schwab M, Gehring M, Nakamura Y, Sugimura T, Terada M et al: Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene 7(6): 1185-1189, 1992.
170. Srivatsan ES, Murali V and Seeger RC: Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma. Prog Clin Biol Res 366: 91-98, 1991.
171. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F and Brodeur GM: Human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305(5931): 245-248, 1983.
172. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F and Alt FW: Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35(2 Pt 1): 359-367, 1983.
173. Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653): 1121-1124, 1984.
174. Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L and Slamon DJ: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271: 41-49, 1988.
175. Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, Eddy J, Gerald WL, Heller G and Cheung NK: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12(12): 2607-2613, 1994.
176. Kleinman NR, Lewandowska K and Culp LA: Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites. Br J Cancer 69(4): 670-679, 1994.
177. Meitar D, Crawford SE, Rademaker AW and Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14(2): 405-414, 1996.
178. Ribatti D, Alessandri G, Vacca A, Iurlaro M and Ponzoni M: Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer 77(3): 449-454, 1998.
179. Ribatti D, Vacca A, Nico B, De Falco G, Giuseppe Montaldo P and Ponzoni M: Angiogenesis and anti-angiogenesis in neuroblastoma. Eur J Cancer 38(6): 750-757, 2002.
180. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK and Reisfeld RA: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44(12 Pt 1): 5914-5920, 1984.
181. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D and Coccia PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45(6): 2642-2649, 1985.
182. Saarinen UM, Coccia PF, Gerson SL, Pelley R and Cheung NK: Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res 45(11 Pt 2): 5969-5975, 1985.
183. Munn DH and Cheung NK: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47(24 Pt 1): 6600-6605, 1987.
184. Munn DH and Cheung NK: Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 170(2): 511-526, 1989.
185. Kushner BH and Cheung NK: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73(7): 1936-1941, 1989.
186. Cheung NK, Medof ME and Munn D: Immunotherapy with GD2 specific monoclonal antibodies. Prog Clin Biol Res 271: 619-632, 1988.
187. Kushner BH, Kramer K and Cheung NK: Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19(22): 4189-4194, 2001.
188. Cheung NK, Kushner BH and Kramer K: Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 15(5): 853-866, 2001.
189. Lode HN, Xiang R, Becker JC, Gillies SD and Reisfeld RA: Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 80(3): 277-292, 1998.
190. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD and Reisfeld RA: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91(5): 1706-1715, 1998.
191. Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM and Becker W: Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer 77(5): 787-795, 1998.
192. Goessling W, McKee PH and Mayer RJ: Merkel cell carcinoma. J Clin Oncol 20(2): 588-598, 2002.
193. Gould VE, Moll R, I, Lee I and Franke WW: Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 52(4): 334-353, 1985.
194. Gould VE, Lee I and Hammar SP: Neuroendocrine skin carcinoma coexpressing cytokeratin and neurofilament proteins. Ultrastruct Pathol 9(1-2): 83-90, 1985.
195. Kivela T and Tarkkanen A: The Merkel cell and associated neoplasms in the eyelids and periocular region. Surv Ophthalmol 35(3): 171-187, 1990.
196. Warner TF, Uno H, Hafez GR, Burgess J, Bolles C, Lloyd RV and Oka M: Merkel cells and Merkel cell tumors. Ultrastructure, immunocytochemistry and review of the literature. Cancer 52(2): 238-245, 1983.
197. Ratner D, Nelson BR, Brown MD and Johnson TM: Merkel cell carcinoma. J Am Acad Dermatol 29(2 Pt 1): 143-156, 1993.
198. Van Gele M, Van Roy N, Ronan SG, Messiaen L, Vandesompele J, Geerts ML, Naeyaert JM, Blennow E, Bar-Am I, Das Gupta TK, van der Drift P, Versteeg R, Leonard JH and Speleman F: Molecular analysis of lp36 breakpoints in two Merkel cell carcinomas. Genes Chromosomes Cancer 23(1): 67-71, 1998.
199. Harnett PR, Kearsley JH, Hayward NK, Dracopoli NC and Kefford RF: Loss of allelic heterozygosity on distal chromosome lp in Merkel cell carcinoma. A marker of neural crest origins? Cancer Genet Cytogenet 54(1): 109-113, 1991.
200. Leonard LH, Cook AL, Nancarrow D, Hayward N, Van Gele M, Van Roy N and Speleman F: Deletion mapping on the short arm of chromosome 1 in Merkel cell carcinoma. Cancer Detect Prev 24(6): 620-627, 2000.
201. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C and Shipley J: Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer 28(1): 121-125, 2000.
202. Sandbrink F, Muller L, Fiebig HH and Kovacs G: Short communication: deletion 7q, trisomy 6 and 11 in a case of Merkel-cell carcinoma. Cancer Genet Cytogenet 33(2): 305-309, 1988.
203. Leonard JH, Williams G, Walters MK, Nancarrow DJ and Rabbitts PH: Deletion mapping of the short arm of chromosome 3 in Merkel cell carcinoma. Genes Chromosomes Cancer 15(2): 102-107, 1996.
204. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat Genet 25(3): 315-319, 2000.
205. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93(9): 691-699, 2001.
206. Van Gele M, Leonard JH, Van Roy N, Cook AL, De Paepe A and Speleman F: Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer 92(3): 409-413, 2001.
207. Leonard JH, Leonard P and Kearsley JH: Chromosomes 1, 11, and 13 are frequently involved in karyotypic abnormalities in metastatic Merkel cell carcinoma. Cancer Genet Cytogenet 67(1): 65-70, 1993.
208. Leonard JH and Hayard N: Loss of heterozygosity of chromosome 13 in Merkel cell carcinoma. Genes Chromosomes Cancer 20(1): 93-97, 1997.
209. Harle M, Arens N, Moll I, Back W, Schulz T and Scherthan H: Comparative genomic hybridization (CGH) discloses chromosomal and subchromosomal copy number changes in Merkel cell carcinomas. J Cutan Pathol 23(5): 391-397, 1996.
210. Larsimont D and Verhest A: Chromosome 6 trisomy as sole anomaly in a primary Merkel cell carcinoma. Virchows Arch 428(4-5): 305-309, 1996.
211. Amo-Takyi BK, Tietze L, Tory K, Guerreiro P, Gunther K, Bhardwaj RS, Mittermayer C and Handt S: Diagnostic relevance of chromosomal in-situ hybridization in Merkel cell carcinoma: targeted interphase cytogenetic tumour analyses. Histopathology 34(2): 163-169, 1999.
212. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C and Knapper WK: Merkel cell carcinoma. Prognosis and management. Arch Surg 126(12): 1514-1519, 1991.
213. Shaw JH and Rumball E: Merkel cell tumour: clinical behaviour and treatment. Br J Surg 78(2): 138-142, 1991.
214. Kokoska ER, Kokoska MS, Collins BT, Stapleton DR and Wade TP: Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg 174(6): 688-693, 1997.
215. Leonard JH, Ramsay JR, Kearsley JH and Birrell GW: Radiation sensitivity of Merkel cell carcinoma cell lines. Int J Radiat Oncol Biol Phys 32(5): 1401-1407, 1995.
216. Wynne CJ and Kearsley JH: Merkel cell tumor. A chemosensitive skin cancer. Cancer 62(1): 28-31, 1988.
217. Pople, IK: Merkel cell tumour of the face successfully treated with radical radiotherapy. Eur J Surg Oncol 14(1): 79-81, 1988.
218. Queirolo P, Gipponi M, Peressini A, Disomma CF, Vecchio S, Raposio E, Guenzi M, Sertoli MR and Cafiero E: Merkel cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease: review of clinical cases. Anticancer Res 17(IB): 673-677, 1997.
219. Gollard R, Weber R, Kosty MP, Greenway HT, Massullo V and Humberson C: Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations Cancer 88(8): 1842-1852, 2000.
220. Fenig E, Brenner B, Katz A, Rakovsky E, ana MB and Sulkes A: The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer 80(5): 881-885, 1997.
221. Pectasides D, Moutzourides G, Dimitriadis M, Varthalitis J and Athanassiou A: Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide. Am J Clin Oncol 18(5): 418-420, 1995.
222. Feun LG, Savaraj N, Legha SS, Silva EG, Benjamin RS and Burgess MA: Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience. Cancer 62(4): 683-685, 1988.
223. Ferrau F, Micali G and Guitart J: Merkel cell carcinoma of the scalp: dramatic resolution with primary chemotherapy. J Am Acad Dermatol 31(2 Pt 1): 271-272, 1994.
224. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G and Mariani L: 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83(2): 372-378, 1998.
225. Fenig E, BrennerB, Njuguna E, Katz A, Schachter J and Sulkes A: Oral etoposide for Merkel cell carcinoma in patients previously treated with intravenous etoposide. Am J Clin Oncol 23(1): 65-67, 2000.
226. Tai PT, Yu E, Winquist E, Hammond, A, Stitt L, Tonita J and Gilchrist J: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18(12): 2493-2499, 2000.
227. Oberndorfer S: Karzinoide tumoren des diinndarms. Frankfurt Zeitschr Pathology 1: 426-432, 1907.
228. Thorson A, Bjork G, Bjorkman G and et al: Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right heart (pulmonary stenosis and tricuspid regurgitation without septal defect), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis. American Heart Journal 47: 795, 1954.
229. Creutzfeldt W and Stockmann F: Carcinoids and carcinoid syndrome. Am J Med 82(5B): 4-16, 1987.
230. McCaughan BC, Martini N and Bains MS: Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg, 89(1): 8-17, 1985.
231. Abidi F, Goel R, Bishop S and Bain M: Peripheral carcinoid of the lung: A clinicopathologic surgery. J Surg Oncol 39: 190-196, 1988.
232. Dusmet M and McKneally MF: Bronchial and thymic carcinoid tumors: a review. Digestion 55 Suppl 3: 70-76, 1994.
233. Salgia R, Skarin AT, Yang F-C, Goldstein ML and Harpole DH: Carcinoid tumors of the lung. Contemporary Surgery 51(3): 135-144, 1997.
234. Loy TS, Darkow GV and Quesenberry JT: Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas. An immunohistochemical study with ultrastructural correlations. Am J Surg Pathol 19(2): 173-182, 1995.
235. Hammar S: Common neoplasms. Pulmonary Pathology 1207-1258, 1994.
236. Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, ubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Chandrasekharappa SC, Crabtree JS, Kim YS, Heppner C, Burns AL, Spiegel AM, Marx SJ, Liotta LA, Collins FS, Travis WD and Emmert-Buck MR: Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 6(13): 2285-2290, 1997.
237. Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, Prauer HW, Werner M and Hofler H: Typical and atypical carcinoid tumors of the lung are characterized by llq deletions as detected by comparative genomic hybridization. Am J Pathol 153(4): 1089-1098, 1998.
238. D'Adda T, Candidus S, Denk H, Bordi C and Hofler H: Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J Pathol 189(3): 394-401, 1999.
239. Gortz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, Saremaslani P, Speel EJ, Heitz PU and Komminoth P: Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 154(2): 429-436, 1999.
240. Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P and Gazdar AF: Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85(3): 600-607, 1999.
241. Kytola S, Hoog A, Nord B, Cedermark B, Frisk T, Larsson C and Kjellman M: Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 158(5): 1803-1808, 2001.
242. Lohmann DR, Fesseler B, Putz B et al: Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 53: 5797-5801, 1993.
243. Lohmann DR, Funk A and Niedermeyer HP: Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol 64: 293-296, 1993.
244. Chakravarthy A and Abrams RA: Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer 75(6): 1386-1390, 1995.
245. Schupak KD and Wallner KE: The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 20(3): 489-495, 1991.
246. Valimaki M, Jarvinen H, Salmela P, Sane T, Sjoblom SM and Pelkonen R: Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67(3): 547-549, 1991.
247. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1(11): 727-740, 1983.
248. Leitner SP, Greenberg P, Danieu LA and Michaelson RA: Partial remission of carcinoid tumor in response to cyproheptadine. Ann Intern Med 111(9): 760-761, 1989.
249. Engstrom PF, Lavin PT, Moertel CG, Folsch E and Douglass HO Jr. Streptozocin plus fiuorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2(11): 1255-1259, 1984.
250. Gregor M: Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment. Digestion 55 Suppl 3: 60-63, 1994.